Keyphrases
Colorectal Cancer
100%
Epidermal Growth Factor Receptor Inhibitors
100%
KRAS Testing
100%
Inhibitor Treatment
100%
Community Setting
100%
EGF Receptor Inhibitors
66%
Metastatic Colorectal Cancer (mCRC)
44%
KRAS mutation
22%
Oncology Care
22%
Genotype
11%
United States
11%
Integrated Health Service Delivery
11%
Electronic Medical Records
11%
Poor Response
11%
Clinical Utilization
11%
Comorbid Conditions
11%
Treatment Decisions
11%
Manual Chart Review
11%
Survival Time
11%
Clinical Practice Guidelines
11%
Age at Diagnosis
11%
Predictive Biomarker
11%
Wild-type KRAS
11%
Clinical Care
11%
Cancer mutations
11%
Colorectal Cancer Diagnosis
11%
Treatment Uptake
11%
Rapid Uptake
11%
Used Electronics
11%
Medicine and Dentistry
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Colorectal Carcinoma
100%
Clinical Oncology
28%
Metastatic Colorectal Cancer
28%
Biological Marker
14%
Survival Time
14%
Cancer Diagnosis
14%
Delivery of Health Care
14%
Electronic Patient Record
14%
Nursing and Health Professions
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Colorectal Carcinoma
100%
Metastatic Colorectal Cancer
28%
Wild Type
14%
Practice Guideline
14%
Integrated Health Care System
14%
Electronic Medical Record
14%
Biological Marker
14%
Cancer Diagnosis
14%
Survival Time
14%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Colorectal Carcinoma
100%
Metastatic Colorectal Cancer
28%
Biological Marker
14%
Survival Time
14%